About Vidium

We envision a world where pet cancer is no longer defined by fear.
Genome

A new way

By informing veterinarians and pet parents about which mutations are causing their pet’s cancer to grow and spread, we intend to open up the use of precision medicine to combat canine cancer in new and more effective ways.

Vidium is dedicated to unravelling the genetic components of common and complex diseases, including cancer. As a result, the practice of medicine targeting these conditions can be more rational, more precise and more personal. Our focus is on shifting paradigms in cancer treatment to enable cures for cancer and other serious diseases in pets through programs at the intersection of personalized medicine and comparative genomics.

Dogs Paw
Genome

Our mission

Providing veterinarians with the very best technology and insight to confidently diagnose and treat pets with cancer.

Genome

What we believe

We believe that when pets win, everyone wins.
Do good science that does good.
All of us are smarter than any of us.
Our pets deserve access to the best medicine that science can provide.
Be a good human, sometimes you can be a hero.
It is our individual weirdness that makes us a better team.
We challenge the impossible.
Our science is unimpeachable.
Man Hughing A Golden Dog
Two Dogs Playing
Two Dogs Smiling On The Desert

Leadership

David Dog David Haworth

David Haworth, DVM, PhD

president and co-founder

William Dog William Hendricks

William Hendricks, PhD

chief scientific officer and founder

Katie Dog Katie Banovich

Katie Banovich

vice president of operations and co-founder

Zhu Dog Zhanyang Zhu

Zhanyang Zhu, PhD

head of bioinformatics and product development

210512 Ch Vidium Leadership Bio Dogs Guannan V1 1guannan Wang Photo Copy

Guannan Wang, PhD

head of clinical curation

210512 Ch Vidium Leadership Bio Dogs Andy Chon V1 210512 Ch Vidium Leadership Bio Light Chon

Esther Chon, DVM, DACVIM (Oncology)

head of veterinary affairs

Luna 420x420 Whitley Bw 420x420

Derick Whitley, DVM, Diplomate ACVP

vice president of strategy, innovation and diagnostics

Genome

Advisory board

210507 Ch Vidium Advisory Board Bio Light Bergman 210507 Ch Vidium Advisory Board Bio Dark Bergman

Phil Bergman

DVM, PhD, DACVIM

210507 Ch Vidium Advisory Board Bio Light Clifford 210507 Ch Vidium Advisory Board Bio Dark Clifford

Craig A. Clifford

DVM, MS, DACVIM (Oncology)

210507 Ch Vidium Advisory Board Bio Light Lorch 210507 Ch Vidium Advisory Board Bio Dark Lorch

Gwendolen Lorch

DVM, MS, PhD

210507 Ch Vidium Advisory Board Bio Light Huentleman 210507 Ch Vidium Advisory Board Bio Dark Huentleman

Matt Huentelman

PhD

210507 Ch Vidium Advisory Board Bio Light Schork 210507 Ch Vidium Advisory Board Bio Dark Schork

Nicholas J. Schork

PhD

210507 Ch Vidium Advisory Board Bio Light Papadopoulos 210507 Ch Vidium Advisory Board Bio Dark Papadopoulos

Nickolas Papadopoulos

PhD

Inlab

Backed by TGen

The Translational Genomics Research Institute (TGen, an Affiliate of City of Hope) is a leader in the genomics revolution. Begun by Dr. Jeffrey M. Trent, the founding Scientific Director of the Human Genome Project, this world-class research institute explores the most advanced areas of genetics in human and animal health. As a subsidiary of TGen, Vidium Animal Health® benefits from the incredible knowledge and research of TGen scientists.